Payment overview · 2025
General Payments
$1,586.89
70 reported records · 17 companies
Healthcare provider profile · identity verified
Ilya Domnich, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine · BROOKLYN, NY · NPI 1699793034
Verified facts
What the public records show
CMS Open Payments records show Ilya Domnich, M.D. received $1,586.89 in general payments during 2025 across 70 reported records.
ABBVIE INC. accounted for 28.6% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 29 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Creon, Edarbi, Farxiga, Linzess, Mounjaro, Ozempic, Rybelsus, Trelegy Ellipta.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported CREON as an associated drug or biological on 91561 records involving 20616 distinct recipient NPIs. Public Medicare Part D data also shows 184 claims for Creon by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 252 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 172 claims for Synthroid by this doctor in 2024.
Amgen Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PROLIA as an associated drug or biological on 20867 records involving 11744 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Prolia by this doctor in 2024.
Astellas Pharma US Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Myrbetriq as an associated drug or biological on 16 records involving 16 distinct recipient NPIs. Public Medicare Part D data also shows 75 claims for Myrbetriq by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 54 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LOKELMA as an associated drug or biological on 6897 records involving 4326 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Lokelma by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NEXIUM as an associated drug or biological on 464 records involving 299 distinct recipient NPIs. Public Medicare Part D data also shows 51 claims for Nexium by this doctor in 2024.
Azurity Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported EDARBI as an associated drug or biological on 1140 records involving 805 distinct recipient NPIs. Public Medicare Part D data also shows 23 claims for Edarbi by this doctor in 2024.
Azurity Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported EDARBYCLOR as an associated drug or biological on 283 records involving 215 distinct recipient NPIs. Public Medicare Part D data also shows 29 claims for Edarbyclor by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 27 claims for Trelegy Ellipta by this doctor in 2024.
IRONWOOD PHARMACEUTICALS, INC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Linzess as an associated drug or biological on 1209 records involving 1184 distinct recipient NPIs. Public Medicare Part D data also shows 252 claims for Linzess by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 63 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 77 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 40 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 167 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Rybelsus by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 586 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $454.01 | 28.6% | 20 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $279.39 | 17.6% | 15 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $180.39 | 11.4% | 9 | 2025 |
| REVANCE THERAPEUTICS, INC. | Unresolved — no canonical attribution shown | $137.72 | 8.7% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $97.35 | 6.1% | 4 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $62.97 | 4.0% | 3 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $59.89 | 3.8% | 3 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $48.53 | 3.1% | 2 | 2025 |
| Ardelyx, Inc. | Unresolved — no canonical attribution shown | $44.03 | 2.8% | 2 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $43.84 | 2.8% | 2 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $43.35 | 2.7% | 2 | 2025 |
| Agios Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $38.38 | 2.4% | 2 | 2025 |
| Azurity Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $25.38 | 1.6% | 1 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $23.33 | 1.5% | 1 | 2025 |
| IRONWOOD PHARMACEUTICALS, INC | Unresolved — no canonical attribution shown | $22.50 | 1.4% | 1 | 2025 |
| Esperion Therapeutics, Inc. | Unresolved — no canonical attribution shown | $19.78 | 1.2% | 1 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $6.05 | 0.4% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,586.89 | 70 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| CREON Normalized: creon |
Drug | ABBVIE INC. | $420.13 | 15 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $279.39 | 15 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $249.70 | 14 | 2025 |
Source payment records
|
|||||
| LINZESS Normalized: linzess |
Drug | ABBVIE INC., IRONWOOD PHARMACEUTICALS, INC | $198.80 | 13 | 2025 |
Source payment records
|
|||||
| DAXXIFY Normalized: daxxify |
Drug | REVANCE THERAPEUTICS, INC. | $137.72 | 1 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $97.35 | 4 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $83.63 | 4 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $71.82 | 4 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $62.97 | 3 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $59.89 | 3 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $53.05 | 2 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $48.53 | 2 | 2025 |
Source payment records
|
|||||
| IBSRELA Normalized: ibsrela |
Drug | Ardelyx, Inc. | $44.03 | 2 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $43.35 | 2 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $43.35 | 2 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $41.03 | 2 | 2025 |
Source payment records
|
|||||
| PYRUKYND Normalized: pyrukynd |
Drug | Agios Pharmaceuticals, Inc. | $38.38 | 2 | 2025 |
Source payment records
|
|||||
| EDARBI Normalized: edarbi |
Drug | Azurity Pharmaceuticals, Inc. | $25.38 | 1 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $24.19 | 1 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $24.19 | 1 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $24.19 | 1 | 2025 |
Source payment records
|
|||||
| CAPVAXIVE Normalized: capvaxive |
Biological | Merck Sharp & Dohme LLC | $23.33 | 1 | 2025 |
Source payment records
|
|||||
| GARDASIL 9 Normalized: gardasil 9 |
Biological | Merck Sharp & Dohme LLC | $23.33 | 1 | 2025 |
Source payment records
|
|||||
| NEXLETOL Normalized: nexletol |
Drug | Esperion Therapeutics, Inc. | $19.78 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $19.65 | 1 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $19.65 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $16.55 | 2 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $15.69 | 1 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $6.05 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| CREON creon |
2025 | Creon | 2024 | 184 | exact normalized | Medicare Part D |
| EDARBI edarbi |
2025 | Edarbi | 2024 | 23 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 54 | exact normalized | Medicare Part D |
| LINZESS linzess |
2025 | Linzess | 2024 | 252 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 77 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 167 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 18 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 27 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | CREON open payments reported associated product |
CMS Open Payments — General Payments 91561 supporting records · 20616 recipient NPIs · example record 1201352608 |
Creon · 2024 Exact normalized brand match · 1 Part D row |
184 | 30 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
252 | 38 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
172 | 28 |
| Amgen Inc. Exact reporting entity; no affiliate inference |
2025 | PROLIA open payments reported associated product |
CMS Open Payments — General Payments 20867 supporting records · 11744 recipient NPIs · example record 1226874448 |
Prolia · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| Astellas Pharma US Inc Exact reporting entity; no affiliate inference |
2025 | Myrbetriq open payments reported associated product |
CMS Open Payments — General Payments 16 supporting records · 16 recipient NPIs · example record 1238599014 |
Myrbetriq · 2024 Exact normalized brand match · 1 Part D row |
75 | 11 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
54 | 15 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | LOKELMA open payments reported associated product |
CMS Open Payments — General Payments 6897 supporting records · 4326 recipient NPIs · example record 1206131624 |
Lokelma · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | NEXIUM open payments reported associated product |
CMS Open Payments — General Payments 464 supporting records · 299 recipient NPIs · example record 1206134180 |
Nexium · 2024 Exact normalized brand match · 1 Part D row |
51 | suppressed by CMS |
| Azurity Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | EDARBI open payments reported associated product |
CMS Open Payments — General Payments 1140 supporting records · 805 recipient NPIs · example record 1242666830 |
Edarbi · 2024 Exact normalized brand match · 1 Part D row |
23 | suppressed by CMS |
| Azurity Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | EDARBYCLOR open payments reported associated product |
CMS Open Payments — General Payments 283 supporting records · 215 recipient NPIs · example record 1242666846 |
Edarbyclor · 2024 Exact normalized brand match · 1 Part D row |
29 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
27 | suppressed by CMS |
| IRONWOOD PHARMACEUTICALS, INC Exact reporting entity; no affiliate inference |
2025 | Linzess open payments reported associated product |
CMS Open Payments — General Payments 1209 supporting records · 1184 recipient NPIs · example record 1227653589 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
252 | 38 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
63 | 18 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
77 | 15 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
40 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
167 | 25 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
18 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
586 | 113 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Amlodipine Besylate | Amlodipine Besylate | 1093 | 230 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 779 | 159 |
| Atorvastatin Calcium | Atorvastatin Calcium | 744 | 183 |
| Metformin Hcl | Metformin Hcl | 659 | 138 |
| Losartan Potassium | Losartan Potassium | 614 | 152 |
| Eliquis | Apixaban | 586 | 113 |
| Levothyroxine Sodium | Levothyroxine Sodium | 566 | 119 |
| Metoprolol Tartrate | Metoprolol Tartrate | 556 | 115 |
| Metoprolol Succinate | Metoprolol Succinate | 500 | 123 |
| Omeprazole | Omeprazole | 469 | 98 |
| Tamsulosin Hcl | Tamsulosin Hcl | 418 | 91 |
| Hydralazine Hcl | Hydralazine Hcl | 384 | 88 |
| Furosemide | Furosemide | 364 | 85 |
| Escitalopram Oxalate | Escitalopram Oxalate | 339 | 58 |
| Pantoprazole Sodium | Pantoprazole Sodium | 328 | 101 |
| Carvedilol | Carvedilol | 292 | 46 |
| Hydrochlorothiazide | Hydrochlorothiazide | 276 | 57 |
| Clopidogrel | Clopidogrel Bisulfate | 259 | 53 |
| Gabapentin | Gabapentin | 259 | 79 |
| Linzess | Linaclotide | 252 | 38 |
| Simvastatin | Simvastatin | 248 | 49 |
| Vascepa | Icosapent Ethyl | 243 | 34 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 214 | 44 |
| Dexlansoprazole Dr | Dexlansoprazole | 209 | 21 |
| Zolpidem Tartrate | Zolpidem Tartrate | 202 | 32 |
| Creon | Lipase/Protease/Amylase | 184 | 30 |
| Finasteride | Finasteride | 180 | 40 |
| Famotidine | Famotidine | 178 | 45 |
| Synthroid | Levothyroxine Sodium | 172 | 28 |
| Memantine Hcl | Memantine Hcl | 170 | 39 |
| Ezetimibe | Ezetimibe | 169 | 26 |
| Donepezil Hcl | Donepezil Hcl | 167 | 33 |
| Lisinopril | Lisinopril | 167 | 36 |
| Ozempic | Semaglutide | 167 | 25 |
| Glipizide | Glipizide | 165 | 47 |
| Januvia | Sitagliptin Phosphate | 161 | 32 |
| Montelukast Sodium | Montelukast Sodium | 157 | 24 |
| Diclofenac Sodium | Diclofenac Sodium | 155 | 39 |
| Trazodone Hcl | Trazodone Hcl | 137 | 22 |
| Valsartan | Valsartan | 136 | 21 |
| Fluticasone Propionate | Fluticasone Propionate | 134 | 49 |
| Atenolol | Atenolol | 127 | 24 |
| Glipizide Er | Glipizide | 125 | 28 |
| Santyl | Collagenase Clostridium Hist. | 123 | 16 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 122 | 37 |
| Sertraline Hcl | Sertraline Hcl | 119 | 30 |
| Entresto | Sacubitril/Valsartan | 116 | 22 |
| Potassium Chloride | Potassium Chloride | 107 | 30 |
| Enalapril Maleate | Enalapril Maleate | 101 | 19 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 100 | 14 |
| Glimepiride | Glimepiride | 100 | 18 |
| Mirtazapine | Mirtazapine | 99 | 22 |
| Duloxetine Hcl | Duloxetine Hcl | 96 | 18 |
| Citalopram Hbr | Citalopram Hydrobromide | 94 | 25 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 88 | 33 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 87 | 18 |
| Labetalol Hcl | Labetalol Hcl | 87 | 19 |
| Memantine Hcl Er | Memantine Hcl | 83 | 15 |
| Nifedipine Er | Nifedipine | 78 | 22 |
| Fenofibrate | Fenofibrate | 77 | 18 |
| Mounjaro | Tirzepatide | 77 | 15 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 77 | 22 |
| Alcohol Prep Pads | Alcohol Antiseptic Pads | 75 | 22 |
| Ibandronate Sodium | Ibandronate Sodium | 75 | 12 |
| Myrbetriq | Mirabegron | 75 | 11 |
| Zenpep | Lipase/Protease/Amylase | 75 | 12 |
| Tradjenta | Linagliptin | 74 | 14 |
| Alendronate Sodium | Alendronate Sodium | 72 | 11 |
| Clonidine Hcl | Clonidine Hcl | 67 | 17 |
| Mupirocin | Mupirocin | 67 | 32 |
| Ranolazine Er | Ranolazine | 66 | 17 |
| Breo Ellipta | Fluticasone/Vilanterol | 65 | 11 |
| Alprazolam | Alprazolam | 63 | 18 |
| Jardiance | Empagliflozin | 63 | 18 |
| Lactulose | Lactulose | 63 | 20 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 63 | 19 |
| Allopurinol | Allopurinol | 62 | 20 |
| Pravastatin Sodium | Pravastatin Sodium | 61 | 15 |
| Clonazepam | Clonazepam | 60 | 18 |
| Icosapent Ethyl | Icosapent Ethyl | 60 | 17 |
| Ketoconazole | Ketoconazole | 59 | 15 |
| Repaglinide | Repaglinide | 59 | suppressed |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 58 | 12 |
| Colchicine | Colchicine | 57 | 16 |
| Benazepril Hcl | Benazepril Hcl | 56 | suppressed |
| Meloxicam | Meloxicam | 56 | 39 |
| Spironolactone | Spironolactone | 56 | suppressed |
| Dapagliflozin | Dapagliflozin Propanediol | 54 | suppressed |
| Dexilant | Dexlansoprazole | 54 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 54 | 15 |
| Irbesartan | Irbesartan | 53 | 11 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 52 | 15 |
| Nexium | Esomeprazole Magnesium | 51 | suppressed |
| Nitroglycerin | Nitroglycerin | 49 | 14 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 49 | 11 |
| Single Use Swab | Alcohol Antiseptic Pads | 48 | 19 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 47 | 15 |
| Easy Touch Alcohol Prep Pads | Alcohol Antiseptic Pads | 47 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 47 | 14 |
| Febuxostat | Febuxostat | 45 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 44 | 11 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 44 | suppressed |
| Azithromycin | Azithromycin | 43 | 40 |
| Lorazepam | Lorazepam | 43 | 13 |
| Xarelto | Rivaroxaban | 43 | 15 |
| Hydrocortisone | Hydrocortisone | 42 | 20 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 42 | 27 |
| Sodium Chloride | 0.9 % Sodium Chloride | 42 | 22 |
| Nebivolol Hcl | Nebivolol Hcl | 41 | suppressed |
| Ramipril | Ramipril | 40 | suppressed |
| Trulicity | Dulaglutide | 40 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 39 | 27 |
| Fentanyl | Fentanyl | 39 | suppressed |
| Procto-Med Hc | Hydrocortisone | 39 | suppressed |
| Amantadine | Amantadine Hcl | 38 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 38 | suppressed |
| Clonidine | Clonidine | 37 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 37 | 21 |
| Pioglitazone Hcl | Pioglitazone Hcl | 37 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 37 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 36 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 36 | 14 |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 36 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 35 | 26 |
| Solifenacin Succinate | Solifenacin Succinate | 35 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 35 | 14 |
| Dutasteride | Dutasteride | 34 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 33 | suppressed |
| Levetiracetam | Levetiracetam | 33 | suppressed |
| Restasis | Cyclosporine | 33 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 32 | 29 |
| Meclizine Hcl | Meclizine Hcl | 32 | 20 |
| Warfarin Sodium | Warfarin Sodium | 32 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 31 | 14 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 31 | 12 |
| Latanoprost | Latanoprost | 31 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 30 | suppressed |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 30 | suppressed |
| Telmisartan | Telmisartan | 30 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 29 | 25 |
| Edarbyclor | Azilsartan Med/Chlorthalidone | 29 | suppressed |
| Calcitriol | Calcitriol | 28 | suppressed |
| Folic Acid | Folic Acid | 28 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 28 | suppressed |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 27 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 27 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 27 | suppressed |
| Bystolic | Nebivolol Hcl | 26 | suppressed |
| Cyproheptadine Hcl | Cyproheptadine Hcl | 26 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 26 | suppressed |
| Betamethasone Dipropionate | Betamethasone Dipropionate | 25 | 18 |
| Ibuprofen | Ibuprofen | 25 | 18 |
| Invokana | Canagliflozin | 25 | suppressed |
| Lidocaine | Lidocaine | 25 | suppressed |
| Metolazone | Metolazone | 25 | suppressed |
| Naproxen | Naproxen | 25 | 21 |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 24 | 17 |
| Sucralfate | Sucralfate | 24 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 23 | suppressed |
| Edarbi | Azilsartan Medoxomil | 23 | suppressed |
| Felodipine Er | Felodipine | 23 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 23 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 23 | suppressed |
| Torsemide | Torsemide | 23 | suppressed |
| Dayvigo | Lemborexant | 22 | suppressed |
| Digoxin | Digoxin | 22 | suppressed |
| Olopatadine Hcl | Olopatadine Hcl | 22 | suppressed |
| Omeprazole-Sodium Bicarbonate | Omeprazole/Sodium Bicarbonate | 22 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 22 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 22 | suppressed |
| Bumetanide | Bumetanide | 21 | suppressed |
| Fludrocortisone Acetate | Fludrocortisone Acetate | 21 | suppressed |
| Gemfibrozil | Gemfibrozil | 21 | suppressed |
| Megestrol Acetate | Megestrol Acetate | 21 | suppressed |
| Repatha Sureclick | Evolocumab | 21 | suppressed |
| Rivastigmine | Rivastigmine | 21 | suppressed |
| Janumet Xr | Sitagliptin Phos/Metformin Hcl | 20 | suppressed |
| Lansoprazole | Lansoprazole | 20 | suppressed |
| Admelog Solostar | Insulin Lispro | 19 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 19 | suppressed |
| Baclofen | Baclofen | 19 | suppressed |
| Cefdinir | Cefdinir | 19 | 18 |
| Chlorthalidone | Chlorthalidone | 19 | suppressed |
| Gemtesa | Vibegron | 19 | suppressed |
| Nystop | Nystatin | 19 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 19 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 19 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 18 | suppressed |
| Prednisone | Prednisone | 18 | 14 |
| Rybelsus | Semaglutide | 18 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 18 | suppressed |
| Bupropion Hcl | Bupropion Hcl | 17 | suppressed |
| Bupropion Xl | Bupropion Hcl | 17 | suppressed |
| Fosfomycin Tromethamine | Fosfomycin Tromethamine | 17 | suppressed |
| Heparin Sodium | Heparin Sodium,porcine | 17 | suppressed |
| Levemir Flexpen | Insulin Detemir | 17 | suppressed |
| Lovastatin | Lovastatin | 17 | suppressed |
| Mupirocin | Mupirocin Calcium | 17 | 12 |
| Risperidone | Risperidone | 17 | suppressed |
| Tobramycin | Tobramycin | 17 | 13 |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 17 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 17 | suppressed |
| Alcohol Pads | Alcohol Antiseptic Pads | 16 | suppressed |
| Dutasteride-Tamsulosin | Dutasteride/Tamsulosin Hcl | 16 | suppressed |
| Enoxaparin Sodium | Enoxaparin Sodium | 16 | suppressed |
| Lagevrio (Eua) | Molnupiravir | 16 | 16 |
| Methenamine Hippurate | Methenamine Hippurate | 16 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 16 | suppressed |
| Telmisartan-Hydrochlorothiazid | Telmisartan/Hydrochlorothiazid | 16 | suppressed |
| Ammonium Lactate | Ammonium Lactate | 15 | suppressed |
| Diazepam | Diazepam | 15 | suppressed |
| Pregabalin | Pregabalin | 15 | suppressed |
| Prolia | Denosumab | 15 | suppressed |
| Silver Sulfadiazine | Silver Sulfadiazine | 15 | suppressed |
| Benicar Hct | Olmesartan/Hydrochlorothiazide | 14 | suppressed |
| Celecoxib | Celecoxib | 14 | suppressed |
| Dabigatran Etexilate | Dabigatran Etexilate Mesylate | 14 | suppressed |
| Levofloxacin | Levofloxacin | 14 | 14 |
| Lokelma | Sodium Zirconium Cyclosilicate | 14 | suppressed |
| Mesalamine | Mesalamine | 14 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 14 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 14 | suppressed |
| Synjardy Xr | Empagliflozin/Metformin Hcl | 14 | suppressed |
| Acarbose | Acarbose | 13 | suppressed |
| Acyclovir | Acyclovir | 13 | suppressed |
| Altace | Ramipril | 13 | suppressed |
| Candesartan Cilexetil | Candesartan Cilexetil | 13 | suppressed |
| Eszopiclone | Eszopiclone | 13 | suppressed |
| Fluconazole | Fluconazole | 13 | 11 |
| Halobetasol Propionate | Halobetasol Propionate | 13 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 13 | suppressed |
| Methimazole | Methimazole | 13 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 13 | suppressed |
| Repatha Syringe | Evolocumab | 13 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 13 | suppressed |
| Alogliptin | Alogliptin Benzoate | 12 | suppressed |
| Benazepril-Hydrochlorothiazide | Benazepril/Hydrochlorothiazide | 12 | suppressed |
| Cefpodoxime Proxetil | Cefpodoxime Proxetil | 12 | 12 |
| Ceftriaxone | Ceftriaxone Sodium | 12 | suppressed |
| Topiramate | Topiramate | 12 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 12 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 11 | suppressed |
| Hydroxyurea | Hydroxyurea | 11 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 11 | suppressed |
| Lunesta | Eszopiclone | 11 | suppressed |
| Matzim La | Diltiazem Hcl | 11 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 11 | suppressed |
| Mometasone Furoate | Mometasone Furoate | 11 | suppressed |
| Nadolol | Nadolol | 11 | suppressed |
| Namzaric | Memantine Hcl/Donepezil Hcl | 11 | suppressed |
| Prochlorperazine Maleate | Prochlorperazine Maleate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,586.89 · 70 records | ABBVIE INC. | ABRYSVO, AIRSUPRA, BREZTRI, CAPLYTA, CAPVAXIVE, COMIRNATY, CREON, DAXXIFY, EDARBI, FARXIGA, GARDASIL 9, IBSRELA, LINZESS, MOUNJARO, NEXLETOL, NURTEC ODT, OTEZLA, Ozempic, PREVNAR 20, PYRUKYND, REPATHA, Rybelsus, TRELEGY ELLIPTA, UBRELVY, VOQUEZNA, VRAYLAR, Veozah, ZAVZPRET, ZEPBOUND | 18 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Creon play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error